Cargando…

TCR-like antibodies in cancer immunotherapy

Cancer immunotherapy has been regarded as the most significant scientific breakthrough of 2013, and antibody therapy is at the core of this breakthrough. Despite significant success achieved in recent years, it is still difficult to target intracellular antigens of tumor cells with traditional antib...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Qinghua, Liu, Zhaoyu, Liu, Zhihua, Lai, Yuxiong, Zhou, Xinke, Weng, Jinsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744646/
https://www.ncbi.nlm.nih.gov/pubmed/31521180
http://dx.doi.org/10.1186/s13045-019-0788-4
_version_ 1783451413991391232
author He, Qinghua
Liu, Zhaoyu
Liu, Zhihua
Lai, Yuxiong
Zhou, Xinke
Weng, Jinsheng
author_facet He, Qinghua
Liu, Zhaoyu
Liu, Zhihua
Lai, Yuxiong
Zhou, Xinke
Weng, Jinsheng
author_sort He, Qinghua
collection PubMed
description Cancer immunotherapy has been regarded as the most significant scientific breakthrough of 2013, and antibody therapy is at the core of this breakthrough. Despite significant success achieved in recent years, it is still difficult to target intracellular antigens of tumor cells with traditional antibodies, and novel therapeutic strategies are needed. T cell receptor (TCR)-like antibodies comprise a novel family of antibodies that can recognize peptide/MHC complexes on tumor cell surfaces. TCR-like antibodies can execute specific and significant anti-tumor immunity through several distinct molecular mechanisms, and the success of this type of antibody therapy in melanoma, leukemia, and breast, colon, and prostate tumor models has excited researchers in the immunotherapy field. Here, we summarize the generation strategy, function, and molecular mechanisms of TCR-like antibodies described in publications, focusing on the most significant discoveries.
format Online
Article
Text
id pubmed-6744646
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67446462019-09-18 TCR-like antibodies in cancer immunotherapy He, Qinghua Liu, Zhaoyu Liu, Zhihua Lai, Yuxiong Zhou, Xinke Weng, Jinsheng J Hematol Oncol Review Cancer immunotherapy has been regarded as the most significant scientific breakthrough of 2013, and antibody therapy is at the core of this breakthrough. Despite significant success achieved in recent years, it is still difficult to target intracellular antigens of tumor cells with traditional antibodies, and novel therapeutic strategies are needed. T cell receptor (TCR)-like antibodies comprise a novel family of antibodies that can recognize peptide/MHC complexes on tumor cell surfaces. TCR-like antibodies can execute specific and significant anti-tumor immunity through several distinct molecular mechanisms, and the success of this type of antibody therapy in melanoma, leukemia, and breast, colon, and prostate tumor models has excited researchers in the immunotherapy field. Here, we summarize the generation strategy, function, and molecular mechanisms of TCR-like antibodies described in publications, focusing on the most significant discoveries. BioMed Central 2019-09-14 /pmc/articles/PMC6744646/ /pubmed/31521180 http://dx.doi.org/10.1186/s13045-019-0788-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
He, Qinghua
Liu, Zhaoyu
Liu, Zhihua
Lai, Yuxiong
Zhou, Xinke
Weng, Jinsheng
TCR-like antibodies in cancer immunotherapy
title TCR-like antibodies in cancer immunotherapy
title_full TCR-like antibodies in cancer immunotherapy
title_fullStr TCR-like antibodies in cancer immunotherapy
title_full_unstemmed TCR-like antibodies in cancer immunotherapy
title_short TCR-like antibodies in cancer immunotherapy
title_sort tcr-like antibodies in cancer immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744646/
https://www.ncbi.nlm.nih.gov/pubmed/31521180
http://dx.doi.org/10.1186/s13045-019-0788-4
work_keys_str_mv AT heqinghua tcrlikeantibodiesincancerimmunotherapy
AT liuzhaoyu tcrlikeantibodiesincancerimmunotherapy
AT liuzhihua tcrlikeantibodiesincancerimmunotherapy
AT laiyuxiong tcrlikeantibodiesincancerimmunotherapy
AT zhouxinke tcrlikeantibodiesincancerimmunotherapy
AT wengjinsheng tcrlikeantibodiesincancerimmunotherapy